There's certainly been issues with how parts of the trial was run. However, it's not insurmountable. It's possible to untangle some of the past data and the trials aren't over yet and these aren't the last trials so we will have better data soon and it could all check out. This vaccine is appealing in particular because it's a lot cheaper to make and a lot more straightforward to distribute and even with questions over how the trials were run it's still looking like the good results will probably hold up mostly.